| scholarly article | Q13442814 |
| P50 | author | Bas D Koster | Q86096547 |
| Tanja D de Gruijl | Q90913412 | ||
| P2093 | author name string | Saskia Vosslamber | |
| Alfons J M van den Eertwegh | |||
| Mari F C M van den Hout | |||
| M Petrousjka van den Tol | |||
| Barbara G Molenkamp | |||
| Berbel J R Sluijter | |||
| Ronald J C L M Vuylsteke | |||
| Tamarah D de Jong | |||
| P2860 | cites work | Activated T cells enhance interferon-α production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. | Q53471242 |
| A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. | Q53619786 | ||
| Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients | Q56901384 | ||
| Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance | Q58729482 | ||
| Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma | Q81019105 | ||
| CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice | Q83201956 | ||
| Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation | Q84547662 | ||
| Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation | Q86623565 | ||
| High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a) | Q91265655 | ||
| Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
| Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma | Q28067023 | ||
| Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial | Q30407940 | ||
| Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma | Q30412300 | ||
| Sex bias in susceptibility to MCMV infection: implication of TLR9. | Q34428264 | ||
| Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma | Q36031518 | ||
| Interferome v2.0: an updated database of annotated interferon-regulated genes | Q36491580 | ||
| Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients | Q36658673 | ||
| Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients | Q36895507 | ||
| Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis | Q37200858 | ||
| Influence of sex hormones on cancer progression | Q37774171 | ||
| Suppressive effects of androgens on the immune system | Q38364572 | ||
| Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells | Q38597659 | ||
| Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade | Q38727885 | ||
| IRF8 Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional and Plasmacytoid Dendritic Cells, Respectively | Q39381290 | ||
| Chronic Type I IFN Is Sufficient To Promote Immunosuppression through Accumulation of Myeloid-Derived Suppressor Cells. | Q40399950 | ||
| Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial | Q40681400 | ||
| IRF5, IRF8, and IRF7 in human pDCs - the good, the bad, and the insignificant? | Q44805973 | ||
| Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials | Q46144219 | ||
| Inflammatory Cytokine Pattern Is Sex-Dependent in Mouse Cutaneous Melanoma Experimental Model. | Q47215215 | ||
| TLR7 escapes X chromosome inactivation in immune cells. | Q47548717 | ||
| CpG oligodeoxynucleotide induces bone marrow precursor cells into myeloid-derived suppressor cells | Q47686838 | ||
| Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual | Q47803820 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | 1708066 | |
| P577 | publication date | 2019-12-26 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma | |
| P478 | volume | 9 |
| Q99552010 | Trial watch: STING agonists in cancer therapy | cites work | P2860 |
Search more.